PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Strong revenue performance across product portfolio.
- Submitted MAA for sepiapterin and BLA for Upstaza.
- Achievement of all planned 2024 clinical and regulatory milestones.
- First quarter 2024 total revenue of $210 million.
- Reaffirmed full year 2024 financial guidance.
- Clinical trial updates for various programs.
- Cash, cash equivalents, and marketable securities of $884.8 million on March 31, 2024.
- None.
Insights
– Strong revenue performance across product portfolio –
– Submitted MAA for sepiapterin and BLA for Upstaza –
– On target to achieve remaining 2024 clinical and regulatory milestones, including global submissions for sepiapterin –
"We are off to a strong start in 2024, with outstanding commercial performance and achievement of all planned clinical and regulatory milestones for the first quarter," said Matthew Klein, M.D., Chief Executive Officer, PTC Therapeutics, Inc. "We remain on track to achieve the many planned 2024 clinical and regulatory milestones, including global regulatory submissions for sepiapterin."
Key Corporate Updates:
- First quarter 2024 total revenue of
$210 million - First quarter 2024 revenue for the DMD franchise was
$161 million - Translarna™ (ataluren) net product revenue was
$104 million - Emflaza® (deflazacort) net product revenue was
$57 million
- Translarna™ (ataluren) net product revenue was
Key Clinical and Regulatory Milestones:
- PTC submitted an MAA to the EMA for sepiapterin for the treatment of PKU in March 2024. The company expects to submit an NDA to the FDA for sepiapterin no later than the third quarter of 2024 and to complete regulatory submissions in
Japan andBrazil in 2024. - PTC submitted a BLA to the FDA for Upstaza™ for the treatment of AADC deficiency in March 2024.
- Based on FDA feedback, PTC plans to resubmit the NDA for Translarna for the treatment of nmDMD in mid-2024.
- Based on FDA feedback, PTC plans to submit an NDA for vatiquinone for the treatment of FA in late 2024.
- The interim data update for the PIVOT-HD trial of PTC518 for HD patients remains on schedule for the second quarter of 2024. This update will include 12-month data on the initial group of subjects for whom data were reported in June 2023, as well as 12-week data on a larger number of stage 2 and stage 3 HD patients.
- PTC expects to report topline data for the CardinALS trial of utreloxastat for ALS in the fourth quarter of 2024.
First Quarter 2024 Financial Highlights:
- Total revenues were
$210.1 million $220.4 million - Total revenue includes net product revenue across the commercial portfolio of
$177.6 million $187.6 million $32.5 million $32.8 million - Translarna net product revenues were
$103.6 million $115.1 million - Emflaza net product revenues were
$57.5 million $54.6 million - Roche reported Evrysdi® 2024 year-to-date sales of approximately
$400 million $31.2 million $30.8 million - Based on U.S. GAAP (Generally Accepted Accounting Principles), GAAP R&D expenses were
$116.1 million $195.1 million - Non-GAAP R&D expenses were
$107.2 million $9.0 million $179.8 million $15.3 million - GAAP SG&A expenses were
$73.3 million $86.9 million - Non-GAAP SG&A expenses were
$63.9 million $9.4 million $73.4 million $13.5 million - Change in the fair value of deferred and contingent consideration was a gain of
$0.1 million $2.4 million - The net loss was
$91.6 million $139.0 million - Cash, cash equivalents, and marketable securities was
$884.8 million $876.7 million - Shares issued and outstanding as of March 31, 2024, were 76,653,960.
PTC Reaffirms Full Year 2024 Financial Guidance:
- PTC anticipates total revenues for full year 2024 to be between
$600 million $680 million - PTC anticipates GAAP R&D and SG&A expense for full year 2024 to be between
$740 $835 million - PTC anticipates Non-GAAP R&D and SG&A expense for full year 2024 to be between
$660 $755 million $65 million $80 million - PTC anticipates up to
$90 million $65 million
Non-GAAP Financial Measures:
In this press release, the financial results of PTC are provided in accordance with GAAP and using certain non-GAAP financial measures. In particular, the non-GAAP R&D and SG&A expense financial measures exclude non-cash, stock-based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management's opinion, these non-GAAP financial measures are useful to investors and other users of PTC's financial statements by providing greater transparency into the historical and projected operating performance of PTC and the company's future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below.
PTC Therapeutics, Inc. | ||||||
Three Months Ended March 31, | ||||||
2024 | 2023 | |||||
Revenues: | ||||||
Net product revenue | $ | 177,604 | $ | 187,557 | ||
Collaboration revenue | - | 6 | ||||
Royalty revenue | 31,154 | 30,831 | ||||
Manufacturing revenue | 1,360 | 1,988 | ||||
Total revenues | 210,118 | 220,382 | ||||
Operating expenses: | ||||||
Cost of product sales, excluding amortization of acquired intangible assets | 14,740 | 14,144 | ||||
Amortization of acquired intangible asset | 51,530 | 39,415 | ||||
Research and development (1) | 116,129 | 195,124 | ||||
Selling, general and administrative (2) | 73,272 | 86,914 | ||||
Change in the fair value of deferred and contingent consideration | (100) | 2,400 | ||||
Total operating expenses | 255,571 | 337,997 | ||||
Loss from operations | (45,453) | (117,615) | ||||
Interest expense, net | (40,834) | (27,331) | ||||
Other income, net | 1,591 | 9,956 | ||||
Loss before income tax expense | (84,696) | (134,990) | ||||
Income tax expense | (6,880) | (3,969) | ||||
Net loss attributable to common stockholders | $ | (91,576) | $ | (138,959) | ||
Weighted-average shares outstanding: | ||||||
Basic and diluted (in shares) | 76,496,127 | 73,729,284 | ||||
Net loss per share—basic and diluted (in dollars per share) | $ | (1.20) | $ | (1.88) | ||
(1) Research and development reconciliation | ||||||
GAAP research and development | $ | 116,129 | $ | 195,124 | ||
Less: share-based compensation expense | 8,967 | 15,314 | ||||
Non-GAAP research and development | $ | 107,162 | $ | 179,810 | ||
(2) Selling, general and administrative reconciliation | ||||||
GAAP selling, general and administrative | $ | 73,272 | $ | 86,914 | ||
Less: share-based compensation expense | 9,411 | 13,501 | ||||
Non-GAAP selling, general and administrative | $ | 63,861 | $ | 73,413 | ||
PTC Therapeutics, Inc. | |||||
March 31, 2024 | December 31, 2023 | ||||
Cash, cash equivalents and marketable securities | $ | 884,813 | $ | 876,739 | |
Total assets | $ | 1,789,629 | $ | 1,895,698 | |
Total debt | $ | 284,512 | $ | 284,213 | |
Total deferred revenue | - | 801 | |||
Total liability for sale of future royalties | 1,838,933 | 1,814,097 | |||
Total liabilities | $ | 2,683,545 | $ | 2,714,253 | |
Total stockholders' deficit (76,653,960 and 75,708,889 common shares issued and outstanding at March 31, 2024, and December 31, 2023, respectively) | $ | (893,916) | $ | (818,555) | |
Total liabilities and stockholders' deficit | $ | 1,789,629 | $ | 1,895,698 | |
PTC Therapeutics, Inc. (in millions) | ||
PTC Therapeutics, Inc. | ||
Reconciliation of GAAP | ||
Milestone Payments | ||
Full Year 2024 | ||
(in millions) | ||
Projected GAAP R&D Expense Related Milestone Payments | $ | 65 |
Projected GAAP Contingent Consideration Payable Related Milestone Payments | 25 | |
Total Projected GAAP Milestone Payments | $ | 90 |
| PTC Therapeutics, Inc. Reconciliation of GAAP to Non-GAAP Projected Full Year 2024 R&D and SG&A Expense | |||||
Low End of Range | High End of Range | ||||
Projected GAAP R&D and SG&A Expense | $ | 740 | $ | 835 | |
Less: projected non-cash, stock-based compensation expense | 80 | 80 | |||
Projected non-GAAP R&D and SG&A expense | $ | 660 | $ | 755 | |
Acronyms:
AADC: Aromatic l-Amino Acid Decarboxylase
ALS: Amyotrophic Lateral Sclerosis
BLA: Biologics License Application
CHF: Confoederatio Helvetica Francs (Swiss francs)
DMD: Duchenne Muscular Dystrophy
EMA: European Medicines Agency
FA: Friedreich Ataxia
FDA:
GAAP: Generally Accepted Accounting Principles
HD: Huntington's Disease
MAA: Marketing Authorization Application
NDA: New Drug Application
nmDMD: Nonsense Mutation Duchenne Muscular Dystrophy
PKU: Phenylketonuria
R&D: Research and Development
SG&A: Selling, General, and Administrative
Today's Conference Call and Webcast Reminder:
To access the call by phone, please click here to register and you will be provided with dial-in details. To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call. The webcast conference call can be accessed on the Investor section of the PTC website at https://ir.ptcbio.com/events-presentations. A replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for 30 days following the call.
About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The company's strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.
For More Information:
Investors:
Kylie O'Keefe
+1 (908) 300-0691
kokeefe@ptcbio.com
Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including the information provided under the heading "PTC Reaffirms Full Year 2024 Revenue Guidance", including with respect to (i) 2024 total revenue guidance, (ii) 2024 GAAP and non-GAAP R&D and SG&A expense guidance and (iii) 2024 acquisition related milestone payment guidance, and statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses, commercialization and other matters with respect to its products and product candidates; PTC's strategy, future operations, future financial position, future revenues, projected costs; the extent, timing and financial aspects of our strategic pipeline prioritization and reductions in workforce; and the objectives of management. Other forward-looking statements may be identified by the words, "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.
PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; PTC's ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in
As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna, Emflaza, Upstaza, Evrysdi, Tegsedi or Waylivra.
The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.
View original content:https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-corporate-update-and-reports-first-quarter-2024-financial-results-302127981.html
SOURCE PTC Therapeutics, Inc.
FAQ
What was PTC Therapeutics' total revenue for the first quarter of 2024?
Which products drove the revenue highlights for PTC Therapeutics in the first quarter of 2024?
What marketing applications did PTC Therapeutics submit in March 2024?
What is PTC Therapeutics' full-year 2024 revenue guidance range?
What was the net loss for PTC Therapeutics in the first quarter of 2024?
